TimesSquare Capital Management’s Bio-Rad Laboratories Class A BIO Stock Holding History

TimesSquare Capital Management’s Portfolio BIO Stock Details BIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-611,335	Closed	-$142M	–	220
2018 Q4	$142M	Buy	611,335 +89,350	+17%	+$24M	1.22%	8
2018 Q3	$163M	Sell	521,985 -26,297	-5%	-$8.16M	1.08%	13
2018 Q2	$158M	Sell	548,282 -32,740	-6%	-$9.04M	1.06%	12
2018 Q1	$145M	Sell	581,022 -26,428	-4%	-$6.73M	0.99%	16
2017 Q4	$145M	Sell	607,450 -57,650	-9%	-$14M	0.95%	17
2017 Q3	$148M	Buy	665,100 +43,450	+7%	+$9.78M	0.99%	13
2017 Q2	$141M	Buy	621,650 +9,950	+2%	+$2.17M	0.91%	22
2017 Q1	$122M	Buy	611,700 +89,800	+17%	+$17.3M	0.79%	28
2016 Q4	$95.1M	Buy	+521,900	New	+$89M	0.64%	41
2013 Q3	–	Sell	-233,404	Closed	-$26.2M	–	243
2013 Q2	$26.2M	Buy	+233,404	New	+$27.4M	0.16%	192

Other funds holding BIO

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

ACM

Atlanta Capital Management Atlanta, Georgia $22.5B AUM 9.67% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

EIP

Easterly Investment Partners Beverly, Massachusetts $1.31B AUM 18.17% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Russell Investments Group London, United Kingdom $93.1B AUM 28.26% 1-Year Est. Return

TimesSquare Capital Management's BIO Position: Q1 2019 in Review

TimesSquare Capital Management sold out of Bio-Rad Laboratories Class A (BIO) in Q1 2019, closing a stake of 611,335 shares — an estimated $142M sold.

TimesSquare Capital Management first reported a position in BIO in Q2 2013 and held it in 10 quarters. The position peaked at $163M in Q3 2018. 346 funds tracked by Wall St. Rank hold BIO as of Q1 2019.

TimesSquare Capital Management reported no remaining Bio-Rad Laboratories Class A position as of Q1 2019 after selling out during the quarter.
TimesSquare Capital Management sold 611,335 Bio-Rad Laboratories Class A shares in Q1 2019, an estimated $142M.
TimesSquare Capital Management first reported a position in Bio-Rad Laboratories Class A in Q2 2013 and held it in 10 quarters.
TimesSquare Capital Management's Bio-Rad Laboratories Class A position peaked at $163M in Q3 2018.
346 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q1 2019.

Based on TimesSquare Capital Management's 13F filing for Q1 2019, filed 10 May 2019.